Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | https://doi.org/10.1186/s12933-024-02190-6 |
| _version_ | 1797247451792408576 |
|---|---|
| author | Phyo T. Htoo Helen Tesfaye Sebastian Schneeweiss Deborah J. Wexler Brendan M. Everett Robert J. Glynn Niklas Schmedt Lisette Koeneman Anouk Déruaz-Luyet Julie M. Paik Elisabetta Patorno |
| author_facet | Phyo T. Htoo Helen Tesfaye Sebastian Schneeweiss Deborah J. Wexler Brendan M. Everett Robert J. Glynn Niklas Schmedt Lisette Koeneman Anouk Déruaz-Luyet Julie M. Paik Elisabetta Patorno |
| author_sort | Phyo T. Htoo |
| collection | DOAJ |
| first_indexed | 2024-04-24T19:58:54Z |
| format | Article |
| id | doaj.art-1b45064e466d4e25abc84ea3e931b788 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-04-24T19:58:54Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-1b45064e466d4e25abc84ea3e931b7882024-03-24T12:09:46ZengBMCCardiovascular Diabetology1475-28402024-03-012311210.1186/s12933-024-02190-6Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE studyPhyo T. Htoo0Helen Tesfaye1Sebastian Schneeweiss2Deborah J. Wexler3Brendan M. Everett4Robert J. Glynn5Niklas Schmedt6Lisette Koeneman7Anouk Déruaz-Luyet8Julie M. Paik9Elisabetta Patorno10Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolMassachusetts General Hospital Diabetes Center, Harvard Medical SchoolDivisions of Cardiovascular and Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolGlobal Epidemiology, Boehringer Ingelheim International GmbH (Germany) DEGlobal Medical Affairs, Lilly Deutschland GmbHGlobal Epidemiology, Boehringer Ingelheim International GmbH (Germany) DEDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical SchoolDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical Schoolhttps://doi.org/10.1186/s12933-024-02190-6 |
| spellingShingle | Phyo T. Htoo Helen Tesfaye Sebastian Schneeweiss Deborah J. Wexler Brendan M. Everett Robert J. Glynn Niklas Schmedt Lisette Koeneman Anouk Déruaz-Luyet Julie M. Paik Elisabetta Patorno Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovascular Diabetology |
| title | Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| title_full | Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| title_fullStr | Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| title_full_unstemmed | Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| title_short | Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| title_sort | correction cardiorenal effectiveness of empagliflozin vs glucagon like peptide 1 receptor agonists final year results from the emprise study |
| url | https://doi.org/10.1186/s12933-024-02190-6 |
| work_keys_str_mv | AT phyothtoo correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT helentesfaye correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT sebastianschneeweiss correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT deborahjwexler correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT brendanmeverett correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT robertjglynn correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT niklasschmedt correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT lisettekoeneman correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT anoukderuazluyet correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT juliempaik correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy AT elisabettapatorno correctioncardiorenaleffectivenessofempagliflozinvsglucagonlikepeptide1receptoragonistsfinalyearresultsfromtheemprisestudy |